ArticleAlimentary pharmacology & therapeutics2016
Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis.
Article in Alimentary pharmacology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Macrophages in Autoimmune Liver Diseases: From Immune Homeostasis to Precision-Targeted Therapy.Biomedicines · 2025Review
- Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray.Hepatology communications · 2025Article
- Article
- Increased CD163+ Macrophage Activation and High Expression of CD163 Promote Granulosa Cell Apoptosis in Polycystic Ovary Syndrome.Journal of inflammation research · 2025Article
- Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy.Biomolecules · 2024Review
- Characteristics of peripheral blood mononuclear cells and potential related molecular mechanisms in patients with autoimmune hepatitis: a single-cell RNA sequencing analysis.Medical molecular morphology · 2024Article
- sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence.Immunity & ageing : I & A · 2024Review
- Macrophage polarization: an important role in inflammatory diseases.Frontiers in immunology · 2024Review
- HERV1-env Induces Unfolded Protein Response Activation in Autoimmune Liver Disease: A Potential Mechanism for Regulatory T Cell Dysfunction.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature.Clinical reviews in allergy & immunology · 2022Review
- Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases.Journal of clinical and translational hepatology · 2022Article
- Circulating complement factor H levels are associated with disease severity and relapse in autoimmune hepatitis.JHEP reports : innovation in hepatology · 2022Article
- Autoimmmune hepatitis.Cellular & molecular immunology · 2022Review
- Macrophage Polarization and Its Role in Liver Disease.Frontiers in immunology · 2021Review
- Leaky Gut Driven by Dysbiosis Augments Activation and Accumulation of Liver MacrophagesFrontiers in immunology · 2021Article
- Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.Frontiers in immunology · 2021Review
- Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension.Frontiers in physiology · 2021Article
- Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys.Journal of personalized medicine · 2020Article
- The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease.Orphanet journal of rare diseases · 2020Article
- Liver Macrophages: Old Dogmas and New Insights.Hepatology communications · 2019Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune hepatitis (AIH) is characterised by liver inflammation with reversibility upon anti-inflammatory treatment. Soluble (s)CD163, a specific macrophage activation marker, is associated with inflammation in other liver diseases, but never investigated in AIH.
aimTo investigate sCD163 in patients with acute AIH and in complete and incomplete responders to standard anti-inflammatory pharmacotherapy, and during follow-up in treatment naive patients.
methodsIn a cross-sectional design, we studied 121 AIH patients (female/male 89/32, median age 49 years); of these, we prospectively studied 10 treatment naïve AIH patients during prednisolone treatment and tapering. Twenty patients had variant syndromes of AIH and primary biliary cholangitis or primary sclerosing cholangitis. sCD163 was compared with markers of disease activity, severity and treatment response.
resultsIn the patients with acute AIH (n = 21), sCD163 was sixfold increased compared with the normalised levels in patients (n = 32) with complete response to standard treatment [9.5 (3.3-28.8) vs. 1.6 (0.8-3.2) mg/L, P < 0.01)], while the patients (n = 27) with incomplete response had higher sCD163 [2.2 (1.3-7.9), P < 0.05] than the complete responders. sCD163 was positively associated with ALAT, IgG and bilirubin (rho: 0.45-0.59, P < 0.001, all), and negatively to external coagulation factors (rho:-0.34, P < 0.001). In the treatment naïve patients, sCD163 fell during high-dose prednisolone treatment and tapering. Immunohistochemical staining confirmed increased CD163 expression in liver biopsies from patients with acute AIH.
conclusionssCD163 was markedly elevated in AIH in the acute phase, normalised by successful treatment in complete responders, but remained higher in the incompletely responding cases. Our results demonstrate macrophage activation in AIH paralleling disease activity, severity and treatment response, suggesting a role for macrophage activation in AIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.